Moreover, the “BioScore” was validated in an independent retrospective cohort of PCa patients exhibiting clinical–histopathologic features similar to those of our original cohort (n = 11, age range, 63 to 77 years; PSA range, 2.4 to 20.0 ng/mL; Gleason score range, 6 (3 + 3) to 9 (4 + 5); tumor–node–metastasis range, pT2c-T3b; follow-up range 24–36 months) with the disease’s clinical progression, defined as above (n = 5 out of 11, time of recurrence range of 4–6 months). The gene discussed is KLK3; the disease is posterior cortical atrophy.